Cencora, Inc. $COR Shares Sold by Westfield Capital Management Co. LP

Westfield Capital Management Co. LP lowered its stake in shares of Cencora, Inc. (NYSE:COR) by 7.0% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 268,752 shares of the company’s stock after selling 20,217 shares during the quarter. Westfield Capital Management Co. LP owned about 0.14% of Cencora worth $80,585,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in COR. Atlantic Edge Private Wealth Management LLC increased its holdings in shares of Cencora by 70.0% in the second quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock valued at $25,000 after purchasing an additional 35 shares during the period. Costello Asset Management INC acquired a new position in Cencora in the 1st quarter valued at $28,000. University of Texas Texas AM Investment Management Co. acquired a new position in Cencora in the 1st quarter valued at $39,000. Caitong International Asset Management Co. Ltd purchased a new position in Cencora during the 2nd quarter worth $61,000. Finally, ANTIPODES PARTNERS Ltd purchased a new stake in shares of Cencora in the second quarter valued at about $61,000. 97.52% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

COR has been the subject of a number of recent analyst reports. Mizuho raised their target price on Cencora from $340.00 to $380.00 and gave the company an “outperform” rating in a report on Thursday, November 6th. Evercore ISI set a $400.00 target price on shares of Cencora and gave the company an “outperform” rating in a report on Thursday, November 6th. Wells Fargo & Company boosted their price target on Cencora from $354.00 to $405.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 11th. TD Cowen raised their price objective on Cencora from $350.00 to $400.00 and gave the company a “buy” rating in a research note on Monday, November 10th. Finally, UBS Group boosted their target price on Cencora from $380.00 to $415.00 and gave the stock a “buy” rating in a research report on Friday, November 7th. Nine research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $371.09.

Cencora Stock Performance

Cencora stock opened at $361.63 on Thursday. The company has a debt-to-equity ratio of 3.64, a quick ratio of 0.53 and a current ratio of 0.90. Cencora, Inc. has a fifty-two week low of $223.92 and a fifty-two week high of $369.00. The stock has a fifty day moving average of $325.26 and a two-hundred day moving average of $303.65. The company has a market capitalization of $70.11 billion, a price-to-earnings ratio of 37.07, a PEG ratio of 1.56 and a beta of 0.63.

Cencora (NYSE:COR) last posted its quarterly earnings data on Wednesday, November 5th. The company reported $3.84 EPS for the quarter, topping analysts’ consensus estimates of $3.79 by $0.05. The firm had revenue of $83.73 billion during the quarter, compared to analysts’ expectations of $83.36 billion. Cencora had a return on equity of 267.36% and a net margin of 0.60%.The firm’s quarterly revenue was up 5.9% compared to the same quarter last year. During the same quarter last year, the business posted $3.34 EPS. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. On average, analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 14th will be paid a dividend of $0.60 per share. The ex-dividend date of this dividend is Friday, November 14th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.7%. This is a boost from Cencora’s previous quarterly dividend of $0.55. Cencora’s dividend payout ratio is currently 30.19%.

Insider Buying and Selling at Cencora

In other news, Chairman Steven H. Collis sold 31,350 shares of the stock in a transaction dated Tuesday, September 16th. The shares were sold at an average price of $289.86, for a total transaction of $9,087,111.00. Following the transaction, the chairman directly owned 305,913 shares in the company, valued at $88,671,942.18. This represents a 9.30% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Robert P. Mauch sold 5,096 shares of the business’s stock in a transaction that occurred on Tuesday, November 18th. The shares were sold at an average price of $366.64, for a total transaction of $1,868,397.44. Following the completion of the sale, the chief executive officer owned 65,746 shares of the company’s stock, valued at approximately $24,105,113.44. The trade was a 7.19% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 46,640 shares of company stock worth $14,099,338 in the last 90 days. Insiders own 10.80% of the company’s stock.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.